Stocktwits on MSN

REPL ignites on doctor fury against FDA’s melanoma drug snub — health sec steps back

FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month citing insufficient data to ...
Seeking Alpha

RFK Jr. says no hand in rejecting Replimune’s lead asset

At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
Blockonomi

Replimune (REPL) Shares Plunge 19% as FDA Issues Second Rejection for Melanoma Treatment

Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial ...

Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision

TheFly reported on April 13 that Jefferies cut its rating on REPL from Buy to Hold and reduced its price target sharply to $2 ...
Stocktwits on MSN

REPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays?

REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma. ・HOTH declined after a $2 million stock offering, along with ...

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives

Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
Yahoo Finance

Replimune Group, Inc. (REPL)

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
Blockonomi

Replimune (REPL) Shares Plunge 19% Following Second FDA Rejection of RP1 Melanoma Treatment

Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma treatment for the second time, citing trial design issues.